RJA
UBX

Raymond James & Associates’s Unity Biotechnology UBX Stock Holding History

Raymond James & Associates’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,275
Closed -$380K – 3720
2019
Q4 		$380K Buy
+5,275
New +$372K ﹤0.01% 2932

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's UBX Position: Q1 2020 in Review

Raymond James & Associates sold out of Unity Biotechnology (UBX) in Q1 2020, closing a stake of 5,275 shares — an estimated $380K sold.

Raymond James & Associates first reported a position in UBX in Q4 2019 and held it in 1 quarter. The position peaked at $380K in Q4 2019. 74 funds tracked by Wall St. Rank hold UBX as of Q1 2020.

  • Raymond James & Associates reported no remaining Unity Biotechnology position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 5,275 Unity Biotechnology shares in Q1 2020, an estimated $380K.
  • Raymond James & Associates first reported a position in Unity Biotechnology in Q4 2019 and held it in 1 quarter.
  • Raymond James & Associates's Unity Biotechnology position peaked at $380K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.